Merck KGaA
MKKGYNext catalyst
Avelumab
Carcinoma, Hepatocellular
Get an email about MKKGY's next catalysts
Track Merck KGaA (MKKGY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
4 upcoming, 1 past
Avelumab Phase 3 Est. Readout
Estimated primary completion for Avelumab trial (NCT03815643) in Solid Tumors. Topline data typically follows completion by weeks to months.
SourceBintrafusp alfa Phase 2 Est. Readout (TRUST)
Estimated primary completion for Bintrafusp alfa trial (NCT04874311) in Advanced Soft-tissue Sarcoma. Topline data typically follows completion by weeks to months.
SourceCetrorelix acetate Phase 3 Est. Readout
Estimated primary completion for Cetrorelix acetate trial (NCT07340827) in Infertility. Topline data typically follows completion by weeks to months.
SourceMirdametinib Phase 2 Est. Readout
Estimated primary completion for Mirdametinib trial (NCT06159166) in NF1. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Single low dose cyclophosphamide
Non-small Cell Lung Cancer
Bintrafusp alfa
Advanced Soft-tissue Sarcoma
F0434
Diabetic Neuropathies
MSJ-0011
Anovulation
Atacicept
Lupus Erythematosus, Systemic
GONAL-f®
Infertility
Pergoveris®
Assisted Reproductive Techniques
Enpatoran
Systematic Lupus Erythematosus
Avelumab Weekly
First Line Non-Small Cell Lung Cancer
Recombinant Human Choriogonadotropin (r-hCG)
Polycystic Ovarian Syndrome
Recombinant human chorionic gonadotrophin (r-hCG)
Infertility
Cladribine High Dose
Generalized Myasthenia Gravis
Encorafenib
BRAF V600E
Recombinant human follicle stimulating hormone (r-hFSH)
Polycystic Ovarian Syndrome
5Fluorouracil
Metastatic Colorectal Cancer
Coriogonadotropin alfa
Infertility
Gonadotropin-releasing hormone (GnRH) analogue
Luteal Hormone Supplementation in In-vitro Fertilization
Avelumab
Carcinoma, Hepatocellular
Recombinant human follicle-stimulating hormone (r-hFSH)
Hypogonadism
RNF
Multiple Sclerosis
Human chorionic gonadotropin (hCG)
Hypogonadism
Cetrorelix acetate
Infertility
Rebif New Formulation + ibuprofen PRN
Relapsing Multiple Sclerosis
Progesterone gel
Infertility
Follicle-stimulating hormone (FSH)
Luteal Hormone Supplementation in In-vitro Fertilization
Saizen®
Idiopathic Short Stature
Tecemotide (L-BLP25)
Non-small Cell Lung Cancer
M7824
Non-small Cell Lung Cancer
Precemtabart tocentecan
Metastatic Colorectal Cancer
Saizen® B
Children Born With Serious Intra-uterine Growth Retardation
Docetaxel
Carcinoma, Non-Small-Cell Lung
Cisplatin
Squamous Cell Carcinoma of the Head and Neck
MSB11022
Psoriasis
Recombinant human chorionic gonadotropin (r-hCG)
Assisted Reproductive Techniques
Bisoprolol/Amlodipine (Amlodipine failed group)
Hypertension
Follitropin alpha
Anovulation
Cilengitide
Glioblastoma
M5049 medium dose
Systemic Lupus Erythematosus
Standard first line treatment with cetuximab + Folfiri
Colorectal Cancer
Recombinant human luteinizing hormone (r-hLH)
Infertility
cilengitide (5-times weekly)
Glioblastoma
M5049 high dose
Systemic Lupus Erythematosus
Interferon beta-1a (Rebif®) alone
Relapsing-Remitting Multiple Sclerosis
M1774
Non-Small Cell Lung Cancer
combination of Avelumab and Cabozantinib
Cancer
Curcumin
Multiple Sclerosis
M5717
Malaria Infection
Lartesertib (M4076)
Ovarian Cancer
r-hLH
Ovarian Stimulation
r-hCG
Ovarian Stimulation
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
Infertility Implantation Failure
Analogous GnRH antagonist
Ovarian Stimulation
AS900672-Enriched
Infertility
Follitropin alfa 150 international unit (IU)
Infertility
Racemate Praziquantel ODT
Schistosomiasis
Enpatoran high dose
Systemic Lupus Erythematosus
Enpatoran medium dose
Systemic Lupus Erythematosus
Avelumab Injection
Gestational Trophoblastic Neoplasias (GTN)
Levo Praziquantel ODT
Schistosomiasis
NKTR-255
Locally Advanced or Metastatic Urothelial Carcinoma
Chemotherapy + Immunotherapy Induction
Muscle-invasive Bladder Cancer
Immunotherapy Maintenance
Muscle-invasive Bladder Cancer
Cisplatin/Carboplatin
Squamous Cell Carcinoma of the Head and Neck
Tepotinib
Carcinoma, Hepatocellular
Pyronaridine
Acute Malaria
GEN-001
Gastric Cancer
M2591
Rheumatoid Arthritis
Peposertib
Locally Advanced Rectal Cancer
Pimasertib
Pancreatic Adenocarcinoma
Nirogacestat
Desmoid Tumor
Cilengitide (2-times weekly)
Glioblastoma
Immune Checkpoint Inhibitor
HCC
Mirdametinib
NF1
Berzosertib
Small-cell Lung Cancer
Nirogacestat Hydrobromide
Desmoid Fibromatosis
Association of berzosertib with gemcitabine
Leiomyosarcoma, Adult
HMBD-001
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
M6223
Locally Advanced or Metastatic Urothelial Carcinoma
M5049
Coronavirus Disease 2019
Tuvusertib (M1774)
Ovarian Cancer
Enpatoran low dose
Systemic Lupus Erythematosus
Atacicept: with loading dose
Rheumatoid Arthritis
Pembrolizumab
Metastatic Colorectal Cancer
FOLFOX
Metastatic Colorectal Cancer
Dose escalation of cetuximab
Colorectal Cancer
Compound 451238
Soft-tissue Sarcoma
M2951
Rheumatoid Arthritis
Vemurafenib and Cobimetinib
Lymphoma, Non-Hodgkin
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Single low dose cyclophosphamide | Phase 3 | Non-small Cell Lung Cancer | - | - |
Bintrafusp alfa | Phase 3 | Advanced Soft-tissue Sarcoma | - | - |
F0434 | Phase 3 | Diabetic Neuropathies | - | - |
MSJ-0011 | Phase 3 | Anovulation | - | - |
Atacicept | Phase 3 | Lupus Erythematosus, Systemic | - | - |
GONAL-f® | Phase 3 | Infertility | - | - |
Pergoveris® | Phase 3 | Assisted Reproductive Techniques | - | - |
Enpatoran | Phase 3 | Systematic Lupus Erythematosus | - | - |
Avelumab Weekly | Phase 3 | First Line Non-Small Cell Lung Cancer | - | - |
Recombinant Human Choriogonadotropin (r-hCG) | Phase 3 | Polycystic Ovarian Syndrome | - | - |
Recombinant human chorionic gonadotrophin (r-hCG) | Phase 3 | Infertility | - | - |
Cladribine High Dose | Phase 3 | Generalized Myasthenia Gravis | - | - |
Encorafenib | Phase 3 | BRAF V600E | - | - |
Recombinant human follicle stimulating hormone (r-hFSH) | Phase 3 | Polycystic Ovarian Syndrome | - | - |
5Fluorouracil | Phase 3 | Metastatic Colorectal Cancer | - | - |
Coriogonadotropin alfa | Phase 3 | Infertility | - | - |
Gonadotropin-releasing hormone (GnRH) analogue | Phase 3 | Luteal Hormone Supplementation in In-vitro Fertilization | - | - |
Avelumab | Phase 3 | Carcinoma, Hepatocellular | - | - |
Recombinant human follicle-stimulating hormone (r-hFSH) | Phase 3 | Hypogonadism | - | - |
RNF | Phase 3 | Multiple Sclerosis | - | - |
Human chorionic gonadotropin (hCG) | Phase 3 | Hypogonadism | - | - |
Cetrorelix acetate | Phase 3 | Infertility | - | - |
Rebif New Formulation + ibuprofen PRN | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Progesterone gel | Phase 3 | Infertility | - | - |
Follicle-stimulating hormone (FSH) | Phase 3 | Luteal Hormone Supplementation in In-vitro Fertilization | - | - |
Saizen® | Phase 3 | Idiopathic Short Stature | - | - |
Tecemotide (L-BLP25) | Phase 3 | Non-small Cell Lung Cancer | - | - |
M7824 | Phase 3 | Non-small Cell Lung Cancer | - | - |
Precemtabart tocentecan | Phase 3 | Metastatic Colorectal Cancer | - | - |
Saizen® B | Phase 3 | Children Born With Serious Intra-uterine Growth Retardation | - | - |
Docetaxel | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Cisplatin | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
MSB11022 | Phase 3 | Psoriasis | - | - |
Recombinant human chorionic gonadotropin (r-hCG) | Phase 3 | Assisted Reproductive Techniques | - | - |
Bisoprolol/Amlodipine (Amlodipine failed group) | Phase 3 | Hypertension | - | - |
Follitropin alpha | Phase 3 | Anovulation | - | - |
Cilengitide | Phase 3 | Glioblastoma | - | - |
M5049 medium dose | Phase 2 | Systemic Lupus Erythematosus | - | - |
Standard first line treatment with cetuximab + Folfiri | Phase 2 | Colorectal Cancer | - | - |
Recombinant human luteinizing hormone (r-hLH) | Phase 2 | Infertility | - | - |
cilengitide (5-times weekly) | Phase 2 | Glioblastoma | - | - |
M5049 high dose | Phase 2 | Systemic Lupus Erythematosus | - | - |
Interferon beta-1a (Rebif®) alone | Phase 2 | Relapsing-Remitting Multiple Sclerosis | - | - |
M1774 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
combination of Avelumab and Cabozantinib | Phase 2 | Cancer | - | - |
Curcumin | Phase 2 | Multiple Sclerosis | - | - |
M5717 | Phase 2 | Malaria Infection | - | - |
Lartesertib (M4076) | Phase 2 | Ovarian Cancer | - | - |
r-hLH | Phase 2 | Ovarian Stimulation | - | - |
r-hCG | Phase 2 | Ovarian Stimulation | - | - |
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) | Phase 2 | Infertility Implantation Failure | - | - |
Analogous GnRH antagonist | Phase 2 | Ovarian Stimulation | - | - |
AS900672-Enriched | Phase 2 | Infertility | - | - |
Follitropin alfa 150 international unit (IU) | Phase 2 | Infertility | - | - |
Racemate Praziquantel ODT | Phase 2 | Schistosomiasis | - | - |
Enpatoran high dose | Phase 2 | Systemic Lupus Erythematosus | - | - |
Enpatoran medium dose | Phase 2 | Systemic Lupus Erythematosus | - | - |
Avelumab Injection | Phase 2 | Gestational Trophoblastic Neoplasias (GTN) | - | - |
Levo Praziquantel ODT | Phase 2 | Schistosomiasis | - | - |
NKTR-255 | Phase 2 | Locally Advanced or Metastatic Urothelial Carcinoma | - | - |
Chemotherapy + Immunotherapy Induction | Phase 2 | Muscle-invasive Bladder Cancer | - | - |
Immunotherapy Maintenance | Phase 2 | Muscle-invasive Bladder Cancer | - | - |
Cisplatin/Carboplatin | Phase 2 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Tepotinib | Phase 2 | Carcinoma, Hepatocellular | - | - |
Pyronaridine | Phase 2 | Acute Malaria | - | - |
GEN-001 | Phase 2 | Gastric Cancer | - | - |
M2591 | Phase 2 | Rheumatoid Arthritis | - | - |
Peposertib | Phase 2 | Locally Advanced Rectal Cancer | - | - |
Pimasertib | Phase 2 | Pancreatic Adenocarcinoma | - | - |
Nirogacestat | Phase 2 | Desmoid Tumor | - | - |
Cilengitide (2-times weekly) | Phase 2 | Glioblastoma | - | - |
Immune Checkpoint Inhibitor | Phase 2 | HCC | - | - |
Mirdametinib | Phase 2 | NF1 | - | - |
Berzosertib | Phase 2 | Small-cell Lung Cancer | - | - |
Nirogacestat Hydrobromide | Phase 2 | Desmoid Fibromatosis | - | - |
Association of berzosertib with gemcitabine | Phase 2 | Leiomyosarcoma, Adult | - | - |
HMBD-001 | Phase 2 | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | - | - |
M6223 | Phase 2 | Locally Advanced or Metastatic Urothelial Carcinoma | - | - |
M5049 | Phase 2 | Coronavirus Disease 2019 | - | - |
Tuvusertib (M1774) | Phase 2 | Ovarian Cancer | - | - |
Enpatoran low dose | Phase 2 | Systemic Lupus Erythematosus | - | - |
Atacicept: with loading dose | Phase 2 | Rheumatoid Arthritis | - | - |
Pembrolizumab | Phase 2 | Metastatic Colorectal Cancer | - | - |
FOLFOX | Phase 2 | Metastatic Colorectal Cancer | - | - |
Dose escalation of cetuximab | Phase 2 | Colorectal Cancer | - | - |
Compound 451238 | Phase 2 | Soft-tissue Sarcoma | - | - |
M2951 | Phase 2 | Rheumatoid Arthritis | - | - |
Vemurafenib and Cobimetinib | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
Frequently asked questions
What is in Merck KGaA's drug pipeline?→
CatalystAlert tracks 88 drug candidates in Merck KGaA's (MKKGY) pipeline across Phase 3, Phase 2. Its lead program is Avelumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Merck KGaA's next FDA catalyst?→
Merck KGaA's (MKKGY) next tracked catalyst is a Phase 3 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MKKGY biotech catalysts?→
Add MKKGY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Merck KGaA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
